Cargando…

Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia

OBJECTIVE: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. STUDY DESIGN: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocente...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavee, Michal, Goldman, Shlomit, Daniel-Spiegel, Etty, Shalev, Eliezer
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733305/
https://www.ncbi.nlm.nih.gov/pubmed/19698156
http://dx.doi.org/10.1186/1477-7827-7-85
Descripción
Sumario:OBJECTIVE: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. STUDY DESIGN: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot. RESULTS: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients. CONCLUSION: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia.